Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WF10 for diabetic foot ulcer and poor glycemic control in type 2 diabetes
ISRCTN12348610Phase 2Completed
- Sponsor
- Oxolife
- Start
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in type 2 diabetes mellitus (T2DM) and diabetic foot ulcer (DFU) comparing WF10 plus standard of care with Standard of care alone (2 arms). Primary endpoint: HbA1c at week 12. Started Nov 2020; status: completed.
02
Drugs
tetrachlorodecaoxide
03
Conditions
type 2 diabetes mellitus (T2DM)diabetic foot ulcer (DFU)
Beyond the preview
Go deeper on ISRCTN12348610.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN12348610.